Cargando…

Tumour microvessel density as predictor of chemotherapy response in breast cancer patients

The aim of this study was to evaluate the predictive value of intratumoural microvessel density in breast cancer. We studied immunohistochemically primary tumours of 104 patients with metastasised breast cancer who took part in a randomised multicentre trial comparing docetaxel to sequential methotr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tynninen, O, Sjöström, J, von Boguslawski, K, Bengtsson, N O, Heikkilä, R, Malmström, P, Østenstad, B, Wist, E, Valvere, V, Saksela, E, Paavonen, T, Blomqvist, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375425/
https://www.ncbi.nlm.nih.gov/pubmed/12085184
http://dx.doi.org/10.1038/sj.bjc.6600325
Descripción
Sumario:The aim of this study was to evaluate the predictive value of intratumoural microvessel density in breast cancer. We studied immunohistochemically primary tumours of 104 patients with metastasised breast cancer who took part in a randomised multicentre trial comparing docetaxel to sequential methotrexate and 5-fluorouracil. Vessels were highlighted with factor VIII staining and counted microscopically. Microvessel density was compared with clinical response to chemotherapy and patient survival. The microvessel density of the primary tumour was not significantly associated with patient's response to chemotherapy, time to progression or overall survival in the whole patient population or in the docetaxel or methotrexate and 5-fluorouracil groups. However, disease-free survival was longer in patients with low microvessel density (P=0.01). These findings suggest that microvessel density of the primary tumour cannot be used as a predictive marker for chemotherapy response in advanced breast cancer. British Journal of Cancer (2002) 86, 1905–1908. doi:10.1038/sj.bjc.6600325 www.bjcancer.com © 2002 Cancer Research UK